AlbaCore Capital Group

AlbaCore Capital Group is a London-based investment firm established in 2016, specializing in private debt and opportunistic credit investments throughout Europe. The firm employs a fundamental research and relative value strategy to enhance capital preservation while seeking attractive returns. AlbaCore focuses on various capital structures and jurisdictions, aiming to deliver strong risk-adjusted returns across both primary and secondary markets. The firm's approach is designed to capitalize on investment opportunities in the European credit landscape.

David Allen

Co-Founder, Chief Investment Officer and Managing Partner

Bill Ammons

Partner and Portfolio Manager

Sheharyar Malik

Director

6 past transactions

Babylon

Post in 2023
Babylon Healthcare Services Limited is a digital health service provider that operates a subscription-based mobile application designed to enhance access to healthcare. Founded in 2013 and headquartered in London, the company also has offices in several global locations, including the United States, Canada, and Malaysia. The Babylon platform enables users to book virtual consultations with general practitioners, receive treatment advice, and obtain prescriptions. It combines artificial intelligence with medical expertise to deliver personalized health assessments and 24/7 access to healthcare professionals through phone or video calls. The app also offers features for users to ask medical questions and monitor their health, promoting proactive healthcare management. Babylon aims to make healthcare accessible and affordable for individuals worldwide, catering to health plans, enterprises, and private users through its digital care tools.

Aero

Series B in 2022
Aero Technologies, Inc. is an online reseller of flight tickets, specializing in matching air travelers with premium seats and shared charters. Based in San Francisco, California, the company offers a range of services, including online flight booking and ticketing, as well as information on flight destinations and current offers. Aero aims to provide an intimate travel experience by offering individual seats with personalized service and flexibility in booking, ensuring a seamless luxury travel experience for its customers. Established in 2013, Aero has positioned itself as a key player in the premium air travel market.

MindMaze

Venture Round in 2022
MindMaze is a company focused on developing medical-grade virtual reality products aimed at stimulating neural recovery. Founded in 2012 and headquartered in Lausanne, Switzerland, with additional locations in Zürich, Ecublens, and San Francisco, MindMaze offers a platform that integrates virtual reality, computer graphics, brain imaging, and neuroscience. Its flagship product, MindMotionPRO, provides engaging virtual reality rehabilitation programs tailored to individual patient needs, allowing clinicians to personalize therapy modalities and optimize rehabilitation delivery in hospital settings. The company's technology encompasses lightweight wearable head-mounted displays, 3D motion capture cameras, and advanced user interfaces, enabling capabilities in gesture recognition and augmented reality. MindMaze also invests in motion capture technology, immersive virtual reality experiences, and neurophysiological measurements, positioning itself at the intersection of gaming, brain-machine control, and healthcare.

Babylon

Debt Financing in 2021
Babylon Healthcare Services Limited is a digital health service provider that operates a subscription-based mobile application designed to enhance access to healthcare. Founded in 2013 and headquartered in London, the company also has offices in several global locations, including the United States, Canada, and Malaysia. The Babylon platform enables users to book virtual consultations with general practitioners, receive treatment advice, and obtain prescriptions. It combines artificial intelligence with medical expertise to deliver personalized health assessments and 24/7 access to healthcare professionals through phone or video calls. The app also offers features for users to ask medical questions and monitor their health, promoting proactive healthcare management. Babylon aims to make healthcare accessible and affordable for individuals worldwide, catering to health plans, enterprises, and private users through its digital care tools.

MindMaze

Venture Round in 2021
MindMaze is a company focused on developing medical-grade virtual reality products aimed at stimulating neural recovery. Founded in 2012 and headquartered in Lausanne, Switzerland, with additional locations in Zürich, Ecublens, and San Francisco, MindMaze offers a platform that integrates virtual reality, computer graphics, brain imaging, and neuroscience. Its flagship product, MindMotionPRO, provides engaging virtual reality rehabilitation programs tailored to individual patient needs, allowing clinicians to personalize therapy modalities and optimize rehabilitation delivery in hospital settings. The company's technology encompasses lightweight wearable head-mounted displays, 3D motion capture cameras, and advanced user interfaces, enabling capabilities in gesture recognition and augmented reality. MindMaze also invests in motion capture technology, immersive virtual reality experiences, and neurophysiological measurements, positioning itself at the intersection of gaming, brain-machine control, and healthcare.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company based in Oakville, Canada, specializing in the development of pharmaceutical cannabidiol (CBD) products and innovative therapies for heart diseases, including acute myocarditis and heart failure. The company's flagship product, CardiolRx, is a pharmaceutically formulated oral CBD designed for clinical applications in treating heart conditions. Additionally, Cardiol Therapeutics is working on advanced nanotechnology to facilitate targeted delivery of CBD and other anti-inflammatory drugs directly to inflamed areas of the heart. The company has received authorization from the United States Food and Drug Administration to conduct clinical studies assessing the efficacy and safety of CardiolRx in various heart diseases, including participation in the Phase II multi-national ARCHER trial. This focus on both cannabinoid-based and anti-inflammatory therapies positions Cardiol Therapeutics at the forefront of addressing significant medical needs in cardiology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.